VCC-001

VCC-001, the most advanced product candidate demonstrated clinical efficacy and a favorable safety profile in several clinical trials. ^{1, 2, 3, 4} The availability of clinical data that have been obtained in >1000 patients reduces risk of failure of future clinical trials I.

Mechanism of action:
Inducing a specific immune response against the
patientʼs tumour based on the individual antigen profile
to enable the immune system to recognize and attack the tumour.

Open graphic as PDF

Only One In 10,000 Substances Tested In Research
Laboratories Will Eventually Become A Drug After About
12 Years. The Cost Is 1–1.5 Billion Us Dollars.

Open Graphic as PDF

Phase III Clinical Study:
VCC-001 has already demonstrated significant
clinical efficacy in phase III in 553 patients with
RCC post-nephrectomy.

Open graphic as PDF

VCC-001 DEMONSTRATED favorable
safety profile in phase III

Open graphic as PDF

• In the Intention to treat population 177 patients received A total of 1053 vaccine doses
• 12 vaccine-related adverse events of mild to moderate severity were noted in two patients
• The higher number of adverse events in the control groups can be accounted for by the higher number of patients
  with tumour progression in this group
• Clinically relevant abnormalities in blood chemistry variables were not recorded

VCC-001 CLINICAL/REGULATORY
ROADMAP 2023

Open graphic as PDF

VCC-002

Open graphic as PDF

VCC-003 / VCC-004

Open graphic as PDF

1. Repmann et al., 2003 Anti Cancer Research 23: 969-974

2. Jocham et al., 2004 Lancet 363:594-99

3. Doehn et al., 2006 Supplement Journal of Urology 5(20): 286

4. May et al., 2009 Cancer Immunol Immunotherap 59(5):687-95